Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold by StockNews.com

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a report released on Tuesday.

Separately, HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Friday, August 16th.

Galectin Therapeutics Stock Performance

Shares of GALT traded down $0.03 during trading hours on Tuesday, reaching $2.60. The stock had a trading volume of 109,152 shares, compared to its average volume of 145,580. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27. The stock has a market capitalization of $161.58 million, a PE ratio of -3.55 and a beta of 0.61. The company's 50-day moving average is $2.54 and its two-hundred day moving average is $2.73.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.04). Equities analysts anticipate that Galectin Therapeutics will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Galectin Therapeutics

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Galectin Therapeutics by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company's stock worth $4,732,000 after acquiring an additional 38,037 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company's stock worth $1,092,000 after purchasing an additional 367,610 shares in the last quarter. Wealthspire Advisors LLC boosted its position in shares of Galectin Therapeutics by 116.7% during the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company's stock worth $952,000 after purchasing an additional 214,512 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Galectin Therapeutics during the 2nd quarter worth about $227,000. Finally, Squarepoint Ops LLC boosted its position in shares of Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company's stock worth $190,000 after purchasing an additional 36,139 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.